Context: Islet transplantation has been shown to improve glucose counterregulation and hypoglycemia symptom recognition in patients with type 1 diabetes (T1D) complicated by severe hypoglycemia episodes and symptom unawareness, but long-term data are lacking.
without problematic hypoglycemia (5) . Unfortunately, despite tremendous advances in the technology available for insulin delivery and glucose monitoring, only 30% of adults with T1D in the United States receiving care at specialty diabetes clinics are achieving HbA 1c levels Ͻ 7.0% (6) . Moreover, 8% reported experiencing severe hypoglycemia resulting in seizure or loss-of-consciousness in the prior 3 months, including 6% of those with HbA 1c levels Ͻ 7.0% (6) . Thus, current data do not support the historical link between HbA 1c levels and severe hypoglycemia risk, and so recommendations to set higher HbA 1c targets are unlikely to impact the burden of severe hypoglycemia in T1D. Moreover, the targeting of higher HbA 1c levels is often not acceptable to patients striving to avoid or mitigate the development of microand macrovascular complications. Clearly, there is a need for further improvement in the approaches to diabetes management in order to realize the benefits of near-normal glycemic control without the accompanying risk for severe hypoglycemia faced by every person with insulin-dependent diabetes.
The risk of experiencing a severe hypoglycemic episode increases with the duration of disease, being 3 times greater with more than 15 years compared to less than 5 years of disease duration (7) . This increased risk with longer disease duration is related to progressive development of compromised physiologic defense mechanisms against a falling plasma glucose concentration in the setting of therapeutic hyperinsulinemia. By 15 years of disease duration most patients with T1D have developed near-total loss of functioning ␤-cells (C-peptide negative) (8) resulting in loss of inhibition of endogenous insulin secretion as well as activation of glucagon secretion in response to declining blood glucose (9) , which together normally increase endogenous (primarily hepatic) glucose production (EGP) to circumvent the development of hypoglycemia. In the absence of these islet cell responses to hypoglycemia, epinephrine secretion and autonomic symptom generation become critical to increase EGP and alert individuals to ingest food (10) . Unfortunately, these sympathoadrenal responses are impaired by recurrent episodes of hypoglycemia leading to a syndrome of hypoglycemia unawareness, also known as hypoglycemia-associated autonomic failure (HAAF) (11) . The presence of impaired awareness of hypoglycemia in T1D is associated with a six-fold increased risk for experiencing severe hypoglycemia (12, 13) , that may be as high as twenty-fold with unawareness (12) . The occurrence of severe hypoglycemia events contributes significantly to diabetes morbidity (6) and mortality (14) .
Importantly, not every patient with reduced awareness of hypoglycemia experiences severe hypoglycemia episodes, and additional risk is imparted by glucose variability (15) , which can also be expressed as glycemic lability when accounting for the time intervals during which glucose levels fluctuate (16) . Considering these interrelated manifestations of "brittle" T1D, a recently proposed definition for problematic hypoglycemia is experiencing two or more episodes of severe hypoglycemia in the past year, or one episode associated with impaired awareness of hypoglycemia, extreme glycemic lability, or major fear and maladaptive behavior (17) . This definition is consistent with criteria used by the Clinical Islet Transplantation (CIT) Consortium for inclusion in trials of islet alone transplantation that utilize simple tools to quantitate impaired awareness of hypoglycemia, hypoglycemia severity, and glycemic lability (18) .
In a prior report involving patients with long-standing C-peptide negative T1D studied before and again 6 months after intrahepatic islet transplantation, we have shown that during insulin-induced hypoglycemia there is restoration of normal inhibition of endogenous insulin secretion, incomplete recovery of glucagon secretion, improvement of epinephrine secretion, and normalization of previously absent autonomic symptoms and EGP (19) . Earlier cross-sectional studies demonstrated similarly incomplete hormonal responses at 6 months (20) and responses at 12 months that were interpreted as absent (21) . Thus, in the present report we address the long-term durability of restored glucose counterregulation by islet transplantation in T1D through reassessment of the previously reported (19) islet recipients 18 months post-transplant using paired hyperinsulinemic-hypoglycemic and euglycemic clamps with measurement of EGP by the isotopic dilution method, and provide measures of glycemic control including by continuous glucose monitoring (CGM) up to 24 months post-transplant.
Subjects and Methods
Subjects included in this study had long-standing C-peptide negative T1D that, despite participation in intensive diabetes management, was complicated by hypoglycemia unawareness (Clarke score Ն 4) and at least one episode of severe hypoglycemia in the prior year associated with a hypoglycemic severity (HYPO) score Ն 1047 and/or a glycemic lability index (LI) Ն433 mmol/L 2 /h⅐wk -1 , and who underwent islet transplantation as part of the CIT07 protocol at the University of Pennsylvania (22) , and were followed for two-years (n ϭ10). One subject who completed the previously reported 6 month glucose counterregulatory testing (19) was unable to complete subsequent CGM or counterregulatory assessments, and so was excluded from this analysis although remained insulin-independent after two islet infusions with HbA 1c 5.7% at two-years post-transplant. The T1D subjects underwent one or two intraportal infusions of islets in order to achieve insulin-independence. Maintenance immunosuppression consisted of low-dose tacrolimus (12-hour blood trough target 3 -6 g/L) and sirolimus (24-hour blood trough target 10 -15 g/L for the first 3 months and 8 -12 g/L thereafter). Two-year outcomes for the entire CIT07 cohort (n ϭ48) has recently been reported (23) .
Healthy nondiabetic control subjects (n ϭ10) were sex-, age-, and BMI-matched to the T1D subjects. The study protocols were approved by the Institutional Review Board of the University of Pennsylvania, and all subjects gave their written informed consent to participate.
Continuous glucose monitoring
T1D subjects were evaluated using a 72-hour continuous glucose monitoring system (CGMS; Medtronic Minimed, Northridge, CA) prior to and at 75 days, 12 months and 24 months following islet transplantation. All subjects utilized a study glucometer (OneTouch Ultra, LifeScan, Milpitas, CA) to calibrate the CGMS 4 times daily with no interval between readings exceeding 12 hours.
Assessment of glucose counterregulation
T1D subjects underwent paired hyperinsulinemic-hypoglycemic and euglycemic clamps prior to and at 6 and 18 months following their final islet infusion. One subject received a second islet infusion after completing the 6 month assessment, and was studied again at 18 months after this final transplant. Each pair of clamps was conducted with at least one week and not more than one month between studies with the order of hypoglycemic vs. euglycemic condition determined by block randomization. T1D subjects were admitted to the Clinical and Translational Research Center the afternoon before study and fasted overnight after 2000 for 12 hours before testing. T1D subjects prior to transplantation were converted from subcutaneous insulin to a low-dose intravenous (IV) insulin infusion at 2100 the evening before study to target blood glucose at 81 -115 mg/dL overnight. By 700, one catheter was placed in an antecubital vein for infusions, and one catheter was placed in a hand or forearm vein for blood sampling, with the hand or forearm placed in a thermoregulated box (ϳ50°C) or heating pad to promote arterialization of venous blood.
At t ϭ-120 minutes a primed (5 mg/kg ⅐fasting plasma glucose in mg/dL/90 for 5 minutes) continuous (0.05 mg⅐kg -1 ⅐min -1 for 355 minutes) infusion of the stable glucose isotope tracer 6,6-2 H 2 -glucose (99% enriched; Cambridge Isotopes Laboratories, Andover, MA) was administered to assess EGP before and during the induction of hyperinsulinemia (24) . When used overnight, the insulin infusion was continued during this period to maintain stable normoglycemia until t ϭ 0. After baseline blood sampling at -20, -10, and -1 minute, at t ϭ0 minutes a continuous infusion of insulin was initiated at 1 mU⅐kg -1 ⅐min -1 for 240-minute to produce hyperinsulinemia. Subsequently, a variable rate infusion of 20% glucose was administered according to the glycemic clamp technique to achieve hourly plasma glucose steps of ϳ80, 65, 55, and 45 mg/dL. To reduce changes in plasma enrichment of 6,6-2 H 2 -glucose during the clamp, the 20% glucose solution was enriched to ϳ2.0% with 6,6-2 H 2 -glucose (24). Plasma glucose was measured every 5 minutes at bedside with an automated glucose analyzer (YSI 2300; Yellow Springs Instruments, Yellow Springs, OH) to adjust the glucose infusion rate and achieve the desired plasma glucose concentration. Additional blood samples for biochemical analysis and an autonomic symptom questionnaire (20) were collected every 20 minutes.
The hyperinsulinemic-euglycemic clamp was conducted as described for the hypoglycemic clamp above but with the target plasma glucose ϳ90 mg/dl for the entire 240-minute study.
All samples were collected on ice into chilled tubes containing EDTA, with Protease Inhibitor Cocktail (Sigma-Aldrich, St. Louis, MO) added to the tubes for peptide hormones, centrifuged at 4°C, separated, and frozen at -80°C for subsequent analysis. Plasma glucose was verified in duplicate by the glucose oxidase method using an automated glucose analyzer (YSI 2300). Plasma insulin, glucagon, and pancreatic polypeptide were measured in duplicate by double-antibody radioimmunoassays (Millipore, Billerica, MA for insulin and glucagon; AL-PCO Diagnostics, Windham, NH for pancreatic polypeptide). Plasma epinephrine was measured by high-performance liquid chromatography (HPLC) with electrochemical detection. Enrichment of 6,6-2 H 2 -glucose was measured by gas chromatography-mass spectrometry. Plasma free fatty acids levels were measured in duplicate using enzymatic colorimetrics (Wako Chemicals, Richmond, VA).
Calculations and statistics
Measures of hypoglycemia unawareness (Clarke score), hypoglycemia severity (HYPO score), and the glycemic lability index (LI) were calculated from questionnaires, event diaries, and self-monitoring of blood glucose records, respectively, as previously described (18) . CGMS measures required Ͼ 48 hours of valid interstitial glucose recording for calculation of glucose mean, SD, CV (25) , proportion of time spent with hyperglycemia (Ͼ180 mg/dL), and proportion of time spent with varying degrees of hypoglycemia (Ͻ70 mg/dL, Ͻ60 mg/dL, and Ͻ 54 mg/ dL) (7, 26) . The rate of appearance (R a ) of glucose during the clamps was calculated using Steele's nonsteady state equation modified for the use of stable isotopes (27) . EGP was calculated from the difference between the rate of appearance of glucose in the plasma and the infusion rate of exogenous glucose. The magnitude of each hormonal, incremental symptom, EGP, and free fatty acid response was assessed as the mean of values obtained during the last 60 minutes of hypoglycemia.
All data are expressed as meanϮSE unless otherwise noted. Comparison of results within the T1D subjects from preto posttransplant times of assessment was performed by Friedman ANOVA, and when significant, pairwise comparisons were performed using the Wilcoxon-matched pairs test, while comparison of results between each T1D time of assessment and nondiabetic controls was performed with the Mann-Whitney U test using Statistica software (StatSoft, Inc., Tulsa, OK). Significance was considered at P Ͻ .05 (two-tailed).
Results

Subject characteristics
The T1D subjects (n ϭ10) had a disease duration of 27 Ϯ 4 years, and were of comparable gender distribution, age, and BMI with the nondiabetic control subjects (n ϭ10; Table 1 ). HbA 1c , which was elevated before, decreased to nondiabetic levels after islet transplantation and remained Յ 6.5% in all subjects during the 24 month follow-up period (P Ͻ .001; Figure 1A ). Insulin require- press.endocrine.org/journal/jcemments were ϳ0.5 U⅐kg -1 ⅐d -1 before transplantation, and were eliminated in all but one subject who returned to requiring ϳ0.1 U⅐kg -1 ⅐d -1 after 12 months to maintain near-normal glycemic control (P Ͻ .001; Figure 1B ). Seven subjects were insulin-independent following one islet infusion, and three were insulin-independent following two islet infusions. The total islet equivalents/kg transplanted per recipient was 9845 Ϯ 685. Subjects maintained appropriate levels of tacrolimus and sirolimus except for two who were unable to tolerate sirolimus and converted to mycophenolate mofetil.
The selection of T1D subjects for the presence of hypoglycemia unawareness, severe hypoglycemia, and marked glycemic lability was reflected in the substantially elevated Clarke score ( Figure 1C ), HYPO score 2769 Ϯ 847, and LI ( Figure 1D) , respectively, before transplantation. Following transplantation, no subject experienced any clinically significant hypoglycemia, the Clarke score became and remained negligible through 24 months (P Ͻ .001; Figure 1C ), the HYPO score became 0 in all subjects when reassessed at 12 months (P Ͻ .01), and LI was markedly reduced at 6 months, becoming negligible by 12 months (P Ͻ .01; Figure 1D ).
Continuous glucose monitoring
CGM demonstrated sustained improvement in mean glucose through 24 months post-transplant (P ϭ .01; Table 2), substantial reduction in glycemic variability assessed as either glucose SD or CV (P ϭ .001 for both; Table  2 ), and almost no time spent hyperglycemic (glucose Ͼ 180 mg/dL) or hypoglycemic (glucose Ͻ 70 mg/dL) (P Ͻ .001 for all comparisons; Table 2 ), such that during the periods of assessment over 24 months Ն 95% of time was spent in the target range of 70 -180 mg/dL (2, 26) .
Counterregulatory responses during the hypoglycemic clamp
The insulin infusion administered during the hypoglycemic clamp resulted in comparable hyperinsulinemia in the T1D subjects preand at 6 and 18 months post-transplant, and in the nondiabetic controls, which was also not different in any group from the hyperinsulinemia achieved during their respective euglycemic control experiments (Figure 2A ). During the hypoglycemic clamp, plasma glucose at the 80 mg/dL step was higher by trend prewhen compared to 6 and 18 months post-transplant (92 Ϯ 4 vs. 82 Ϯ 2 vs. 82 Ϯ 1 mg/dL; P ϭ .07) and when compared to control (81 Ϯ 2 mg/dL; P Ͻ .05), and thereafter was comparable at the 65 (66 Ϯ 2 vs. 63 Ϯ 2 vs. 66 Ϯ 1 vs. 65 Ϯ 1), 55 (55 Ϯ 2 vs. 52 Ϯ 2 vs. 55 Ϯ 1 vs. 57 Ϯ 1), and 45 (46 Ϯ 1 vs. 45 Ϯ 1 vs. 46 Ϯ 1 vs. 49 Ϯ 1) mg/dL hourly steps, whereas during the euglycemic clamp, plasma glucose remained between 85 -90 mg/dL ( Figure 2B ). Plasma enrichment of 6,6-2 H 2 -glucose increased modestly from baseline to 100 minutes and was stable thereafter, and is given together with the glucose R a and glucose infusion rates during the clamps in the Supplementary Figure. Glucagon failed to activate during the hypoglycemic clamp in the T1D subjects pretransplant (PϽ0.01 vs. controls), with levels not different than under euglycemic conditions, whereas glucagon increased during the hypoglycemic clamp in the T1D subjects at 6 and 18 months posttransplant (P Ͻ .01 each vs. pretransplant), albeit incompletely to levels less than in controls (P Ͻ .05 for both 6 and 18 months vs. controls; Figure 3A ; Table 3 ). The pancreatic polypeptide response was substantially impaired in the T1D subjects pretransplant (PϽ0.01 vs. controls), and improved at 6 and 18 months post-transplant (P Յ .01 each vs. pretransplant), although again to levels less than in controls (P Ͻ .05 for 6 months and P ϭ .06 for 18 months vs. controls; Figure 3B ; Table 3 ).
Epinephrine secretion was markedly impaired during hypoglycemia in the T1D subjects pretransplant (PϽ0.01 vs. controls), and improved at 6 and 18 months post-transplant (P Ͻ .01 each vs. pretransplant), with the magnitude of the response still less than in controls at 6 months (P Ͻ .01), and increasing to levels not different than in controls at 18 months (P Ͻ .01 vs. 6 months; Figure 3C ; Table 3 ). Autonomic symptoms were greatly diminished during hypoglycemia in the T1D subjects pretransplant (PϽ0.01 vs. controls), with scores not different than under euglycemic conditions, with a trend for improved symptom responses at 6 months (P ϭ .1 vs. pretransplant) that was significant at 18 months (P Ͻ .01 vs. pretransplant) and not different at either time after transplantation from that in controls ( Figure 3D ; Table 3 ). EGP was suppressed during the hypoglycemic clamp in the T1D subjects pretransplant (PϽ0.01 vs. controls) to levels not different than under euglycemic conditions, whereas EGP increased in response to hypoglycemia at 6 and 18 months post-transplant (P Ͻ .05 each vs. pretransplant) such that the magnitude of the response was not different than in controls ( Figure 3E ; Table 3 ). Free fatty acid levels were suppressed during the hypoglycemic clamp in the T1D subjects pretransplant (PϽ0.01 vs. controls), but increased in response to hypoglycemia at 6 and 18 months post-transplant (P Յ .01 each vs. pretrans- HbA 1c ) , B, insulin requirements, C, hypoglycemia unawareness (Clarke score), and D, glycemic lability index (LI) in subjects with type 1 diabetes (n ϭ10) before and at various intervals after islet transplantation to 24 months. In A, normal data for HbA 1c are derived from the nondiabetic control subjects (n ϭ10). In B, post-transplant insulin use is accounted for by one subject who received a second islet infusion after 6 months, was insulin free at 12 months following this second islet infusion, and returned to insulin use thereafter. In C, a Clarke score of 4 or more indicates reduced awareness of hypoglycemia. In D, the LI requires records of 4 or more self-monitoring blood glucose values daily, which were only available for a subset of the cohort at 12 months post-transplant (n ϭ6). The box plots represent the median, upper and lower quartiles, mean (Ⅺ), and range (error bars). 
Data are means Ϯ SE. Evaluable CGMS data was available for all (n ϭ 10) but one subject at 75 days and one different subject at 24 months posttransplant. a P value for Friedman ANOVA comparison of results within the T1D subjects from pre-to post-transplant times of assessment.
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Discussion
These results indicate that intrahepatic islet transplantation can lead to long-term improvement in glucose counterregulation and hypoglycemia symptom recognition in T1D where these responses to insulin-induced hypoglycemia were absent prior to transplantation. While the partial glucagon response seen at 6 months remained incomplete at 18 months, the epinephrine response that was only partially improved at 6 months became fully normalized at 18 months, with a similar effect seen for pancreatic polypeptide secretion, a marker of parasympathetic (vagal) activation, and autonomic symptom generation. The additional improvement in the epinephrine response from 6 to 18 months is best explained by the longer duration without exposure to hypoglycemia as documented by CGM allowing for complete reversal of HAAF, and indicates that recovery of autonomic nervous system function in those most severely affected by HAAF requires similar avoidance of hypoglycemia for more than a 6 month period. Glucose counterregulation is best defined by the increase in EGP that is ultimately required to circumvent the development of low blood glucose. Here, there is the appearance of a delay in the partial glucagon response to hypoglycemia. This finding is consistent with the hypothesis that intrahepatic glucose release may attenuate the exposure of intrahepatic islets to peripheral hypoglycemia (28) . It is possible that release of glucagon from islets within the liver may create an early increase in EGP with subsequent attenuation in the stimulated glucagon levels measured peripherally, yet avoiding the development of low blood glucose. Unfortunately, the increasing plasma enrichment of glucose during the first 100 minutes reported here precludes making comparisons of EGP during this time. As previously reported (19) the incomplete glucagon together with a partial epinephrine response at 6 months following transplantation was associated with normal EGP and free fatty acid responses to insulin-induced hypoglycemia. And while only one of our subjects required low-dose insulin treatment post-transplant, a cross-sectional study of insulin-dependent islet transplant recipients demonstrated modest increments in glucagon and epinephrine with partial recovery of EGP seen over the suppressed rates observed in T1D subjects (29) . Thus, improvement of glucose counterregulation is observed as well in islet transplant recipients with partial graft function that can explain the protection afforded by islet grafts against problematic hypoglycemia even when insulin is required to maintain near-normoglycemia.
Indeed, CGM studies have demonstrated similar reductions in mean glucose, glucose variability, and time spent hypoglycemic (Ͻ54 mg/dL) relative to T1D for both insulin-independent and insulin-requiring islet recipients (30, 31) . That the islet graft is responsible for these improvements in CGM measures of glycemic control is supported by the demonstration of significant continuous associations with stimulated C-peptide levels in islet transplant recipients (32) . Thus, while the substantially improved CGM measures of glycemic control reported here may be required over the long-term to fully reverse HAAF, even partial improvements in glucose counterregulation and hypoglycemia symptom recognition likely work in concert with reduced glucose variability to provide the robust protection from hypoglycemia afforded by Figure 2 . Plasma insulin, A, and glucose, B, during the hyperinsulinemic hypoglycemic clamp in type 1 diabetes subjects before (-f-) and at 6 months (--) and 18 months (-OE-) following islet transplantation (n ϭ 10), and in nondiabetic control subjects (--, n ϭ 10). The shaded area represents the 95% confidence interval (CI) for data derived from the hyperinsulinemic euglycemic control experiments (n ϭ 40).
islet transplantation. The parent CIT07 study recently reported 93% probability for remaining free of severe hypoglycemia events for up to 2 years post-transplant (23) .
Interestingly, similar protection from hypoglycemia as demonstrated here for T1D patients undergoing intrahepatic islet allo-transplantation has not been observed for chronic pancreatitis patients undergoing total pancreatectomy with islet auto-transplantation (TPIAT). CGM study of insulin-independent TPIAT recipients has demonstrated ϳ15% of time spent Ͻ 70 mg/dL (33) , similar to that observed in our T1D subjects before transplantation and quite different from the Ͻ 4% of time documented over 24 months following islet allo-transplantation. As most hypoglycemic episodes reported in TPIAT patients occur postprandially, alimentary hypoglycemia attributable to the roux-en-Y gastrointestinal (GI) reconstruction seems the most plausible explanation, with the reported impairments in glucagon secretion and autonomic symptoms (33) reflecting the induction of HAAF, rather than its reversal as demonstrated here for islet allo-transplantation.
While our subjects all participated in intensive diabetes Figure 3 . Counterregulatory hormone (glucagon, A, pancreatic polypeptide, B, epinephrine, C), autonomic symptom, D, endogenous glucose production, E, and free fatty acid, D, responses during the hyperinsulinemic hypoglycemic clamp in type 1 diabetes subjects before (-f-) and at 6 months (--) and 18 months (-OE-) following islet transplantation (n ϭ 10), and in nondiabetic control subjects (--, n ϭ 10). The shaded area represents the 95% CI for data derived from the hyperinsulinemic euglycemic control experiments (n ϭ 40). The preand 6 month post-transplant data contributed to a prior report (ref. 19 ).
doi: 10.1210/jc.2016-1649 press.endocrine.org/journal/jcem 7 management prior to their selection for islet transplantation, many T1D patients experiencing problematic hypoglycemia are not receiving such care. Participation in structured education programs and optimization of insulin delivery and glucose monitoring including with use of insulin pumps and real-time CGM as appropriate and if available can lead to a reduction in severe hypoglycemia events, improved hypoglycemia awareness, and decreased measures of hypoglycemia severity (34); however, none of these approaches have improved mean glucose or HbA1c in this population (35) . An algorithm has been proposed for the implementation of educational and technologic interventions prior to consideration of isolated islet or whole pancreas transplantation to address problematic hypoglycemia (17) . Evaluation of specific interventions in T1D patients with hypoglycemia unawareness have shown that real-time CGM with (36) or without (37) automated insulin suspension via communication to an insulin pump can lower rates of severe hypoglycemia, but without improving the epinephrine response to insulininduced hypoglycemia or hypoglycemia awareness.
In conclusion, patients with long-standing T1D experiencing problematic hypoglycemia despite intensive diabetes management can achieve durable improvement in glucose counterregulation and hypoglycemia symptom recognition with intrahepatic islet transplantation. This is the first report in patients with Ͼ 15 years disease duration and absent glucose counterregulation and hypoglycemia symptom recognition prior to intervention evidencing normalization of the epinephrine response to hypoglycemia. Remarkably, the recovery of glucose counterregulation with islet allo-transplantation is associated with nearnormal glycemic control assessed over 2 years with almost no time spent hypoglycemic (Ͻ70 mg/dL). These results are distinct from those reported with TPIAT for chronic pancreatitis, and from outcomes seen with nontransplant interventions for T1D. Whole pancreas transplantation (38) remains the only alternative treatment for patients with T1D and problematic hypoglycemia that has been shown to achieve a composite endpoint of HbA 1c Ͻ7.0% and elimination of severe hypoglycemia as reported for islet transplantation by several multicenter trials at 1 (39) and 2 (23, 40) years post-transplant. While presently the adverse effects of the required immunosuppression preclude broad application in T1D, islet transplantation should be considered as a treatment option for patients with problematic hypoglycemia failing nontransplant interventions. The magnitude of each hormonal, incremental symptom, endogenous glucose production, and free fatty acid response to insulin-induced hypoglycemia was assessed as the mean of values obtained during the last 60 min of each hypoglycemic clamp.
b The pre-and 6 month post-transplant data contributed to a prior report (ref. 19 ). c P value for Friedman ANOVA comparison of results within the T1D subjects from pre-to post-transplant times of assessment.
* P Ͻ 0.05 for comparison to T1D subjects before transplantation. **P Յ 0.01 for comparison to T1D subjects before transplantation.
¶ P ϭ 0.1 for comparison to T1D subjects before transplantation. † P Ͻ 0.05 for comparison to T1D subjects 6 months after islet transplantation. ‡ P Ͻ 0.01 for comparison to T1D subjects 6 months after islet transplantation. § P Ͻ 0.05 for comparison to T1D subjects 18 months after islet transplantation.
£P ϭ 0.06 for comparison to T1D subjects 18 months after islet transplantation. 
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